


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

What is claimed is

1. (Previously Presented) A compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;


R¹ is SR⁶, SOR⁶, or SO₂R⁶,

wherein R⁶ is a C₃₋₇cycloalkyl or C₃₋₇cycloalkenyl group;


R² and R³ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl, and C₁₋₆haloalkyl;

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;

Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$, and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, $-OR^{11}$ or $-NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, halo C_{1-4} alkyl, $-OR^{11}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $-OC(O)NR^{11}R^{12}$, R^{11} and R^{12} independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4.

2. (Currently Amended) A compound according to Claim 1, wherein R^8 is selected from the group consisting of halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$, or $OC(O)NR^{11}R^{12}$, and $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring.


3. (Previously Presented) A compound according to claim 1 wherein R^1 represents $-SO_2R^6$.

4. (Previous Presented) A compound according to claim 1 wherein R^6 represents a C_{3-7} cycloalkyl group.


5. (Previously Presented) A compound according to claim 1 wherein R^2 and R^3 each represent hydrogen.

6. (Previously Presented) A compound according to claim 1 wherein R^4 and R^5 are independently selected from hydrogen and methyl.

7. (Currently Amended) A compound according to claim 1 wherein Ar is selected from a group (a) or (b):




(a)



(b)

8. (Original) A compound of formula (Ia):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R¹ is SR⁶, SOR⁶, or SO₂R⁶,

wherein R⁶ is a C₃₋₇cycloalkyl or C₃₋₇cycloalkenyl group;

R² and R³ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl, and C₁₋₆haloalkyl; and

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4.

9. (Previously Presented A compound according to claim 1 wherein m is 5 or 6 and n is 3 or 4.

10. (Previously Presented) A compound selected from the group consisting of:

4-((1*R*)-2-[(6-[4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol (Isomer 1);

4-((1*R*)-2-[(6-[4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol (Isomer 2);

4-((1*R*)-2-[(6-[4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[4-[4-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[(4-[3-(Cyclohexylsulfonyl)phenyl]butyl)oxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[(4-[3-(3-Cyclopenten-1-ylsulfonyl)phenyl]butyl)oxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[(5-[3-(Cyclopentylsulfonyl)phenyl]pentyl)oxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(7-[(3-(Cyclopentylsulfonyl)phenyl]propyl)oxy}heptyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

4-((1*R*)-2-[(6-[(4-[3-(Cyclopentylsulfonyl)-5-methylphenyl]butyl)oxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

N-[5-((1*R*)-2-[(6-[(4-[3-(Cyclopentylsulfonyl)phenyl]butyl)oxy}hexyl)amino]-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide;

4-((1*R*)-2-[[6-{4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy]hexyl]amino)-1-hydroxyethyl)-2-fluorophenol;
6-{2-[[6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)pyridin-3-ol;
5-((1*R*)-2-[[6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-8-hydroxy-3,4-dihydroquinolin-2(1*H*)-one;
5-((1*R*)-2-[[6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-hydroxyphenylformamide;
salts thereof, solvates thereof, and physiologically functional derivatives thereof.

11. (Previously Presented) A compound according to Claim 10 which is:

4-((1*R*)-2-[[6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
or a salt, solvate, or physiologically functional derivative thereof.

12. (Previously Presented) A compound according to claim 1 in the form of a salt formed with an arylsulphonic acid.


13. (Previously Presented) A compound according to claim 8 which is selected from the group consisting of:

4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl) phenol 4-methylbenzenesulfonate;
4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol 4-bromobenzene sulfonate;
4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol 4-chlorobenzene sulfonate
4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol 3-toluene sulfonate;
4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl) phenol 4-biphenyl sulfonate; and
4-((1*R*)-2-[[6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}

hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol,naphthalene-2-sulfonate.

14. (Original) A compound according to claim 13 wherein the salt is in crystalline form.

15. (Currently Amended) A method for the ~~prophylaxis or~~ treatment of a clinical condition in a mammal, for which a selective β_2 -adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;


R¹ is SR⁶, SOR⁶, or SO₂R⁶,

wherein R⁶ is a C₃₋₇cycloalkyl or C₃₋₇cycloalkenyl group;


R² and R³ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl, and C₁₋₆haloalkyl;

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;

Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein R⁸ represents hydrogen, halogen, -(CH₂)₃OR¹¹, -NR¹¹C(O)R¹², -NR¹¹SO₂R¹²,

-SO₂NR¹¹R¹², -NR¹¹R¹², -OC(O)R¹³ or OC(O)NR¹¹R¹²,

and R⁷ represents hydrogen, halogen, or C₁₋₄ alkyl;

or R⁸ represents -NHR¹⁴ and R⁷ and -NHR¹⁴ together form a 5- or 6- membered heterocyclic ring;

R⁹ represents hydrogen, halogen, -OR¹¹ or -NR¹¹R¹².

R¹⁰ represents hydrogen, halogen, haloC₁₋₄ alkyl, -OR¹¹, -NR¹¹R¹², -OC(O)R¹³ or OC(O)NR¹¹R¹².

R¹¹ and R¹² each independently represents hydrogen or C₁₋₄ alkyl, or in the groups -NR¹¹R¹², -SO₂NR¹¹R¹² and -OC(O)NR¹¹R¹², R¹¹ and R¹² independently represent hydrogen or C₁₋₄ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring.


R¹³ represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy or halo C₁₋₄ alkyl; and

g is zero or an integer from 1 to 4

~~according to claim 4 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.~~

16. (Canceled)

17. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that $m + n$ is 5 to 19;


R^1 is SR^6 , SOR^6 , or SO_2R^6 ,

wherein R^6 is a C_{3-7} cycloalkyl or C_{3-7} cycloalkenyl group;


R^2 and R^3 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo, phenyl, and C_{1-6} haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein R⁸ represents hydrogen, halogen, -(CH₂)_qOR¹¹, -NR¹¹C(O)R¹², -NR¹¹SO₂R¹², -SO₂NR¹¹R¹², -NR¹¹R¹², -OC(O)R¹³ or OC(O)NR¹¹R¹², and R⁷ represents hydrogen, halogen, or C₁₋₄ alkyl;

or R⁸ represents -NHR¹⁴ and R⁷ and -NHR¹⁴ together form a 5- or 6- membered heterocyclic ring;

R⁹ represents hydrogen, halogen, -OR¹¹ or -NR¹¹R¹²;

R¹⁰ represents hydrogen, halogen, haloC₁₋₄ alkyl, -OR¹¹, -NR¹¹R¹², -OC(O)R¹³ or OC(O)NR¹¹R¹²;


R¹¹ and R¹² each independently represents hydrogen or C₁₋₄ alkyl, or in the groups -NR¹¹R¹², -SO₂NR¹¹R¹² and -OC(O)NR¹¹R¹², R¹¹ and R¹² independently represent hydrogen or C₁₋₄ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R¹³ represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy or halo C₁₋₄ alkyl; and

q is zero or an integer from 1 to 4

according to claim 1 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

18. (Currently Amended) A combination comprising a compound of formula (I):



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;


R¹ is SR⁶, SOR⁶, or SO₂R⁶.

wherein R⁶ is a C₃₋₇cycloalkyl or C₃₋₇cycloalkenyl group;


R² and R³ are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl, and C₁₋₆haloalkyl;

R⁴ and R⁵ are independently selected from hydrogen and C₁₋₄alkyl with the proviso that the total number of carbon atoms in R⁴ and R⁵ is not more than 4;

Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, $-(CH_2)_3OR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$,

$-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$,

and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring;

R^9 represents hydrogen, halogen, $-OR^{11}$ or $-NR^{11}R^{12}$.

R¹⁰ represents hydrogen, halogen, halo C₁₋₄ alkyl, -OR¹¹, -NR¹¹ R¹², -OC(O)R¹³ or OC(O)NR¹¹R¹².

R¹¹ and R¹² each independently represents hydrogen or C₁₋₄ alkyl, or in the groups -NR¹¹R¹², -SO₂NR¹¹R¹² and -OC(O)NR¹¹R¹², R¹¹ and R¹² independently represent hydrogen or C₁₋₄ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring.

R¹³ represents an aryl group which may be unsubstituted or substituted by one or more substituents selected from halogen, C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy or halo C₁₋₄ alkyl; and

g is zero or an integer from 1 to 4

~~according to claim 4~~ or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients.

19-21. (Canceled)

22. (Previously Presented) A compound according to claim 1, wherein R¹³ is a phenyl group.

23. (Previously Presented) A compound according to claim 1, wherein R¹³ is a naphthyl group.

24. (Previously Presented) A method according to Claim 15, wherein the mammal is a human.

25-34 (Canceled)

35. (New) A method according to Claim 15, wherein the clinical condition is asthma.

36. (New) A method according to Claim 15, wherein the clinical condition is COPD.